Viatris Inc (MIL:1VTRS)
€ 12.41 0 (0%) Market Cap: 14.94 Bil Enterprise Value: 28.03 Bil PE Ratio: 0 PB Ratio: 0.79 GF Score: 43/100

Q3 2024 Viatris Inc Earnings Call Transcript

Nov 07, 2024 / 01:30PM GMT
Release Date Price: €12.02 (+9.57%)
Philippe Martin Viatris Inc;Chief R;D Officer

&

(Technical difficulty)

Products are focused. Execution on the services pipeline gives us confidence in our ability to continue to grow our base business and address unmet medical need. Fixer is a great example. Last month, we announced positive top-line results that demonstrated the efficacy and safety of a fixer for the treatment of generalized anxiety disorder or GAD Japanese patients with moderate to severe disease. We believe the significant lifecycle opportunity and the potential to be a meaningful treatment option for patients with GAD. The condition, which currently does not have any approved treatment available in Japan, we are targeting to submit an application to the Japanese health authorities in 2025. The growth. Our base business is critical for us to be able to reinvest in our innovative pipeline as we look for opportunities which can make a meaningful difference in patients' lives. We also have a unique opportunity to leverage our global development expertise and broad commercial infrastructure Tech Flex. The

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot